Terms: = Head and neck cancer AND RAF1, Raf-1, 5894, P04049, ENSG00000132155, c-Raf, CRAF AND Treatment
44 results:
1. Decabromodiphenyl ether exposure reduces dabrafenib sensitivity of papillary thyroid carcinoma harboring BRAF
Wang X; Cui X; Wang Y; Wang Q; Sun F; Liu Z
Toxicology; 2024 May; 504():153807. PubMed ID: 38641160
[TBL] [Abstract] [Full Text] [Related]
2. Case report: Complete response of an anaplastic thyroid carcinoma patient with
Gui L; Zhu Y; Li X; He X; Ma T; Cai Y; Liu S
Front Immunol; 2023; 14():1178682. PubMed ID: 37122752
[TBL] [Abstract] [Full Text] [Related]
3. Driving role of head and neck cancer cell secretome on the invasion of stromal fibroblasts: Mechanistic insights by phosphoproteomics.
Prieto-Fernandez L; Villaronga MLA; Hermida-Prado F; Hijazi M; Montoro-Jimenez I; Pevida M; Llames S; Rodrigo JP; Cutillas P; Calvo F; Garcia-Pedrero JM; Alvarez-Teijeiro S
Biomed Pharmacother; 2023 Feb; 158():114176. PubMed ID: 36916400
[TBL] [Abstract] [Full Text] [Related]
4. EBV LMP1-C terminal binding affibody molecule downregulates MEK/ERK/p90RSK pathway and inhibits the proliferation of nasopharyngeal carcinoma cells in mouse tumor xenograft models.
Guo Y; Kamara S; Zhang J; Wen H; Zheng M; Liu Y; Zhou L; Chen J; Zhu S; Zhang L
Front Cell Infect Microbiol; 2022; 12():1078504. PubMed ID: 36683690
[TBL] [Abstract] [Full Text] [Related]
5. RREB1 promotes the development of parafollicular carcinogenesis through the Ras-raf-1-ELK3 signaling pathway.
Ma S; Wang H; Li W; Yan Z; Luo X; Lu P
Nucleosides Nucleotides Nucleic Acids; 2022; 41(10):972-981. PubMed ID: 35737446
[TBL] [Abstract] [Full Text] [Related]
6. raf1 promotes lymphatic metastasis of hypopharyngeal carcinoma via regulating LAGE1: an experimental research.
Li Y; Pan M; Lu T; Yu D; Liu C; Wang Z; Hu G
J Transl Med; 2022 Jun; 20(1):255. PubMed ID: 35668458
[TBL] [Abstract] [Full Text] [Related]
7. The Association of the BRAF-V600E Mutation with the Expression of the Molecular Markers in the Primary Tumor and Metastatic Tissue in Papillary Thyroid cancer.
Spirina LV; Chizhevskaya SY; Kovaleva IV; Kondakova IV
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2017-2024. PubMed ID: 34319022
[TBL] [Abstract] [Full Text] [Related]
8. Impact of Race and Insurance Status on Primary treatment for HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
Habib AM; Carey RM; Prasad A; Mady LJ; Shinn JR; Bur AM; Brody RM; Cannady SB; Rajasekaran K; Ibrahim SA; Newman JG; Brant JA
Otolaryngol Head Neck Surg; 2022 Jun; 166(6):1062-1069. PubMed ID: 34253112
[TBL] [Abstract] [Full Text] [Related]
9. Proteomic and phosphoproteomic profiling of shammah induced signaling in oral keratinocytes.
Patil S; Bhat MY; Advani J; Mohan SV; Babu N; Datta KK; Subbannayya T; Rajagopalan P; Bhat FA; Al-Hebshi N; Sidransky D; Gowda H; Chatterjee A
Sci Rep; 2021 Apr; 11(1):9397. PubMed ID: 33931671
[TBL] [Abstract] [Full Text] [Related]
10. EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer.
Ma W; Concha-Benavente F; Santegoets SJAM; Welters MJP; Ehsan I; Ferris RL; van der Burg SH
PLoS One; 2018; 13(9):e0203402. PubMed ID: 30192802
[TBL] [Abstract] [Full Text] [Related]
11. [Inhibition of Yiqi Jiedu formula on proliferation of nasopharyngeal carcinoma cells by MAPK/ERK signaling pathway].
Hu J; Dai N; Xu BY; Zhou FL; Lin T; Luo JJ; Fan JY; He YC
Zhongguo Zhong Yao Za Zhi; 2018 Mar; 43(6):1221-1227. PubMed ID: 29676132
[TBL] [Abstract] [Full Text] [Related]
12. Identification of gene expression models for laryngeal squamous cell carcinoma using co-expression network analysis.
Yang CW; Wang SF; Yang XL; Wang L; Niu L; Liu JX
Medicine (Baltimore); 2018 Feb; 97(7):e9738. PubMed ID: 29443735
[TBL] [Abstract] [Full Text] [Related]
13. Antimetastatic potentials of salvianolic acid A on oral squamous cell carcinoma by targeting MMP-2 and the c-raf/MEK/ERK pathway.
Fang CY; Wu CZ; Chen PN; Chang YC; Chuang CY; Lai CT; Yang SF; Tsai LL
Environ Toxicol; 2018 May; 33(5):545-554. PubMed ID: 29385302
[TBL] [Abstract] [Full Text] [Related]
14. Screening for Thyroid cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Lin JS; Bowles EJA; Williams SB; Morrison CC
JAMA; 2017 May; 317(18):1888-1903. PubMed ID: 28492904
[TBL] [Abstract] [Full Text] [Related]
15. Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid cancer.
Wei WJ; Sun ZK; Shen CT; Song HJ; Zhang XY; Qiu ZL; Luo QY
Theranostics; 2017; 7(4):987-1001. PubMed ID: 28382170
[TBL] [Abstract] [Full Text] [Related]
16. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid cancer.
Beadnell TC; Mishall KM; Zhou Q; Riffert SM; Wuensch KE; Kessler BE; Corpuz ML; Jing X; Kim J; Wang G; Tan AC; Schweppe RE
Mol Cancer Ther; 2016 Aug; 15(8):1952-63. PubMed ID: 27222538
[TBL] [Abstract] [Full Text] [Related]
17. Selective use of sorafenib in the treatment of thyroid cancer.
Pitoia F; Jerkovich F
Drug Des Devel Ther; 2016; 10():1119-31. PubMed ID: 27042004
[TBL] [Abstract] [Full Text] [Related]
18. Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells.
Hanly EK; Tuli NY; Bednarczyk RB; Suriano R; Geliebter J; Moscatello AL; Darzynkiewicz Z; Tiwari RK
Oncotarget; 2016 Feb; 7(8):8676-87. PubMed ID: 26735176
[TBL] [Abstract] [Full Text] [Related]
19. Aggressive thyroid cancer: targeted therapy with sorafenib.
Corrado A; Ferrari SM; Politti U; Mazzi V; Miccoli M; Materazzi G; Antonelli A; Ulisse S; Fallahi P; Miccoli P
Minerva Endocrinol; 2017 Mar; 42(1):64-76. PubMed ID: 26112458
[TBL] [Abstract] [Full Text] [Related]
20. Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers.
Mazumdar T; Sen B; Wang Y; Peng S; Nicholas C; Glisson BS; Myers JN; Johnson FM
Anticancer Drugs; 2015 Sep; 26(8):835-42. PubMed ID: 26053277
[TBL] [Abstract] [Full Text] [Related]
[Next]
